This brand name is authorized in Cyprus, Germany, Israel, Turkey
The drug CEFURAX contains one active pharmaceutical ingredient (API):
|
1
Cefuroxime
UNII R8A7M9MY61 - CEFUROXIME SODIUM
|
|
Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J01DC02 | Cefuroxime | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: DE | Bundesinstitut für Arzneimittel und Medizinprodukte | Identifier(s): 00964123, 00964146, 00964152, 00964169, 07701869, 07701881, 07701898, 11054499, 16596615 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 4740, 4741 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8680638270017, 8680638270024 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
